Related Experiment Videos

p53-independent induction of apoptosis by cyclin-dependent kinase inhibition

Y Shibata1, S Nishimura, A Okuyama

  • 1Department of Radiology, Nagasaki University, School of Dentistry, Japan.

Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research
|July 1, 1996
PubMed

Insights

Inhibition of cyclin-dependent kinases (cdks) can trigger apoptosis, a form of cell death, independent of p53. This occurs during the G1-S cell cycle transition, suggesting aberrant cell cycle machinery can induce self-elimination.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Apoptosis, or programmed cell death, is often linked to the G1 checkpoint and terminal differentiation.
  • The tumor suppressor protein p53 plays a crucial role in initiating apoptosis.
  • However, p53-independent apoptosis can occur during development and in malignant cell differentiation.

Purpose of the Study:

  • To investigate whether inhibiting cyclin-dependent kinase (cdk) activity can induce apoptosis independently of p53.
  • To determine the role of cell cycle progression in p53-independent apoptosis induced by cdk inhibition.

Main Methods:

  • Utilized a specific inhibitor targeting cyclin-dependent kinases (cdks).
  • Examined the induction of apoptotic cell death during the G1-S transition of the cell cycle.
  • Assessed the effect of cell cycle arrest in G1 on the apoptotic process.

Main Results:

  • Inhibition of cdk activity alone was sufficient to induce apoptotic cell death.
  • This p53-independent apoptosis occurred during the G1-S transition.
  • The apoptotic process involved overriding the G1-S boundary and was prevented by G1 arrest.

Conclusions:

  • Aberrant cell cycle machinery can trigger self-elimination (apoptosis) even in the absence of functional p53.
  • Cyclin-dependent kinase (cdk) activity is not essential for this p53-independent apoptotic pathway.
  • Targeting cdks may offer novel therapeutic strategies for cancers with p53 mutations.

Related Concept Videos